menu search

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) Pre-launch commercial activities continue in preparation for potential approval and launch of ONS-5010 ISELIN, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. […] The post Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provide... Read More
Posted: May 15 2023, 12:05
Author Name: forextv
Views: 102011

Search within

Pages Search Results: